Limoges research teams shone at the 21st Annual Days of the Cancéropôle Grand Sud-Ouest (GSO), held from November 26 to 28, 2025, in Agen. A dedicated film highlighted their advances in oncology, emphasizing regional excellence in translational research. This major event brought together researchers and clinicians to exchange on cancer innovations.

​

Focus on CRIBL Laboratory

The CRIBL (Control of B Immune Response and Lymphocytes) laboratory in Limoges plays a central role in this spotlight, with pioneering work on B cell dysfunctions involved in hematological cancers. Located on the Health Campus, the laboratory benefits from close synergy with Limoges University Hospital, fostering innovative projects in onco-hematology. Its three specialized teams explore genetics, immunology, and immuno-oncology to decipher carcinogenic mechanisms.

​

Key Projects on B Lymphoproliferative Disorders

• Lymphomas: The team studies the earliest stages of B lymphoma formation, as illustrated by a recent publication in Blood Advances on initial mechanisms. Innovative murine models reproduce lymphomagenesis linked to mutations like MYD88.

• ​
• Myelomas and Amyloidosis: CRIBL leads the National Reference Center for Amyloidosis and Monoclonal Gammopathies, with advances on AL amyloidosis through lectures at the ISA 2024 congress. Projects like BioPIC strengthen international collaborations.
• ​
• Leukemias: Research focuses on malignant transformations of B lymphocytes, integrating cytometry and bioinformatics to identify therapeutic targets.
• ​
• Waldenström’s Disease: Studies on the MYD88 L265P mutation (present in 90% of cases) and interactions with mast cells, with advanced modeling published in Frontiers in Immunology.

These contributions, featured in the 2025 Days film, position Limoges as a hub of excellence in B onco-hematology, serving targeted and innovative therapies.

Photo ©Cancéropôle GSO